Population
Nox2-/- mice and matched wild-type (WT) controls
Comparison
Subcutaneous Angiotensin II or chronic… vs Wild-type controls without intervention, and…
Design
Preclinical
Follow-up
2 weeks
Authors
Loading...
Preclinical findings do not support clinical use of Nox2 inhibitors; leaves open translation to human cardiac fibrosis.
Aldosterone-dependent activation of a Nox2-containing NADPH oxidase is a key mechanism mediating Angiotensin II-induced and mineralocorticoid-dependent interstitial cardiac fibrosis.
Cave et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: